Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.010
L. Shao, Wenqian Song, Ni Wang, Shihang Zhou
Objective To investigate the identification and characteristics of anti-HI compound antibody with wide thermal amplitude. Methods In March 2017, one pregnant woman with positive irregular antibody who identified irregular antibody specificity in Blood Group Research Department of Dalian Blood Center was selected as the object of this study. The pregnant woman was 27 years old, with AB, RhD positive blood group, and 37 weeks pregnant. In the past, this pregnant woman had a surviving child through caesarean section, and no history of blood transfusion. A volume of 5 mL peripheral blood was collected from pregnant women and her husband for blood group identification, direct anti-human globulin test, and screening and identification of irregular antibodies. Saline tube method was used for blood group identification. Direct anti-human globulin test used tube method. Screening and identification of immunoglobulin (Ig) M irregular antibodies used saline test tube method. This study was in line with World Medical Association Declaration of Helsinki revised in 2013 and informed contents were obtained from the subjects. Results ① The forward grouping of the pregnant women was A1B, the reverse grouping results were negative for A cells, weak agglutination for B cells and 2+ agglutination for O cells. The results of forward and reserve grouping of ABO blood group were not conformed, and irregular antibodies were present. ② The results of direct anti-human globulin test in this pregnant woman showed that both anti-IgG and anti-C3d were negative. ③ The results of antibody screening test showed there was IgM anti-HI compound antibody with wide thermal amplitude in her plasma. Conclusions For patients carried anti-IH compound antibody with wide thermal amplitade, their compound antibody should be screened and identificated by various methods and reagents. And avoid transfusion of ABO mismatched red blood cells for these patients. Key words: Antibodies; Anti-HI; Compound antibody; Transfusion; Antibody screening; Pan-agglutination
{"title":"Detection of compound antibody of anti-HI with wide thermal amplitude in plasma of a pregnant woman","authors":"L. Shao, Wenqian Song, Ni Wang, Shihang Zhou","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.010","url":null,"abstract":"Objective \u0000To investigate the identification and characteristics of anti-HI compound antibody with wide thermal amplitude. \u0000 \u0000 \u0000Methods \u0000In March 2017, one pregnant woman with positive irregular antibody who identified irregular antibody specificity in Blood Group Research Department of Dalian Blood Center was selected as the object of this study. The pregnant woman was 27 years old, with AB, RhD positive blood group, and 37 weeks pregnant. In the past, this pregnant woman had a surviving child through caesarean section, and no history of blood transfusion. A volume of 5 mL peripheral blood was collected from pregnant women and her husband for blood group identification, direct anti-human globulin test, and screening and identification of irregular antibodies. Saline tube method was used for blood group identification. Direct anti-human globulin test used tube method. Screening and identification of immunoglobulin (Ig) M irregular antibodies used saline test tube method. This study was in line with World Medical Association Declaration of Helsinki revised in 2013 and informed contents were obtained from the subjects. \u0000 \u0000 \u0000Results \u0000① The forward grouping of the pregnant women was A1B, the reverse grouping results were negative for A cells, weak agglutination for B cells and 2+ agglutination for O cells. The results of forward and reserve grouping of ABO blood group were not conformed, and irregular antibodies were present. ② The results of direct anti-human globulin test in this pregnant woman showed that both anti-IgG and anti-C3d were negative. ③ The results of antibody screening test showed there was IgM anti-HI compound antibody with wide thermal amplitude in her plasma. \u0000 \u0000 \u0000Conclusions \u0000For patients carried anti-IH compound antibody with wide thermal amplitade, their compound antibody should be screened and identificated by various methods and reagents. And avoid transfusion of ABO mismatched red blood cells for these patients. \u0000 \u0000 \u0000Key words: \u0000Antibodies; Anti-HI; Compound antibody; Transfusion; Antibody screening; Pan-agglutination","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"425-428"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44269549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.013
Yao Chao, Yanping Ma
Multiple myeloma (MM) is one of the most common types of malignant plasmacytosis. At present, most MM patients still cannot be cured. With rapid development of immunotherapy based on hematological malignancies, the use of antibody-drug conjugate (ADC) GSK2857916 has become a new research hot spot in the treatment of relapsed/refractory multiple myeloma (RRMM). GSK2857916 specifically binds to target cell surface through monoclonal antibodies of B cell maturation antigen (BCMA). Then GSK2857916 is rapidly internalized by the target cell, and plays the role of killing MM cells by releasing the active drug mcMMAF. GSK2857916 is one of the promising immunotherapies for the treatment of RRMM. It has high safety and significant clinical efficacy in the treatment of RRMM patients. This article reviews advances in the study of ADC targeting BCMA in the treatment of RRMM, in order to evaluate the safety and tolerance of GSK2857916 monotherapy for RRMM, and further improve the efficacy and prognosis of patients with RRMM. Key words: Multiple myeloma; B-cell maturation antigen; Recurrence; Clinical trial; GSK2857916
{"title":"Research progress of antibody-drug conjugate targeting B cell maturation antigen in treatment of relapsed/refractory multiple myeloma","authors":"Yao Chao, Yanping Ma","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.013","url":null,"abstract":"Multiple myeloma (MM) is one of the most common types of malignant plasmacytosis. At present, most MM patients still cannot be cured. With rapid development of immunotherapy based on hematological malignancies, the use of antibody-drug conjugate (ADC) GSK2857916 has become a new research hot spot in the treatment of relapsed/refractory multiple myeloma (RRMM). GSK2857916 specifically binds to target cell surface through monoclonal antibodies of B cell maturation antigen (BCMA). Then GSK2857916 is rapidly internalized by the target cell, and plays the role of killing MM cells by releasing the active drug mcMMAF. GSK2857916 is one of the promising immunotherapies for the treatment of RRMM. It has high safety and significant clinical efficacy in the treatment of RRMM patients. This article reviews advances in the study of ADC targeting BCMA in the treatment of RRMM, in order to evaluate the safety and tolerance of GSK2857916 monotherapy for RRMM, and further improve the efficacy and prognosis of patients with RRMM. \u0000 \u0000 \u0000Key words: \u0000Multiple myeloma; B-cell maturation antigen; Recurrence; Clinical trial; GSK2857916","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"441-445"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41529541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.001
X. Dai, Gang Xu, Wei Hu
Blood borne pathogens can cause transfusion transmitted diseases. The detection ability of blood borne pathogens in blood services is closely related to the level of blood safety. To explore the metagenomics of blood borne pathogens in blood donors is helpful to formulate corresponding prevention strategies for transfusion transmitted diseases and to improve blood safety. This article reviews the techniques and basic procedures of metagenome detection of blood borne pathogens, as well as the metagenome data in blood donors. The development of detection techniques in the blood borne pathogens metagenome is also prospected. Key words: Blood-borne pathogens; Metagenome; High-throughput nucleotide sequencing; Blood; Blood safety; Blood donors
{"title":"Advances in metagenomics techniques of blood borne pathogens in blood donors","authors":"X. Dai, Gang Xu, Wei Hu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.001","url":null,"abstract":"Blood borne pathogens can cause transfusion transmitted diseases. The detection ability of blood borne pathogens in blood services is closely related to the level of blood safety. To explore the metagenomics of blood borne pathogens in blood donors is helpful to formulate corresponding prevention strategies for transfusion transmitted diseases and to improve blood safety. This article reviews the techniques and basic procedures of metagenome detection of blood borne pathogens, as well as the metagenome data in blood donors. The development of detection techniques in the blood borne pathogens metagenome is also prospected. \u0000 \u0000 \u0000Key words: \u0000Blood-borne pathogens; Metagenome; High-throughput nucleotide sequencing; Blood; Blood safety; Blood donors","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"369-373"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43755133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.012
Q. Cheng
Extramedullary myeloma (EMM) refers to the presence of clonal plasma cells outside the bone marrow in a patient with multiple myeloma (MM). The development of novel agents and hematopoietic stem cell transplantation (HSCT) significantly extend the survival of patients with MM, but none of the current treatments can completely overcome the adverse prognosis of EMM, and the prognosis of EMM is still poor. It is important to understand the current status of EMM treatments and explore new therapies to improve the prognosis of EMM. This article summarizes the recent advances in the treatment of EMM, including chemotherapy, HSCT, cellular immunotherapy and molecular targeted therapy. Key words: Multiple myeloma; Antineoplastic combined chemotherapy protocols; Hematopoietic stem cell transplantation; Molecular targeted therapy; Extramedullary myeloma; Chimeric antigen receptor-based immunotherapy
{"title":"Research progress on treatment of extramedullary myeloma","authors":"Q. Cheng","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.012","url":null,"abstract":"Extramedullary myeloma (EMM) refers to the presence of clonal plasma cells outside the bone marrow in a patient with multiple myeloma (MM). The development of novel agents and hematopoietic stem cell transplantation (HSCT) significantly extend the survival of patients with MM, but none of the current treatments can completely overcome the adverse prognosis of EMM, and the prognosis of EMM is still poor. It is important to understand the current status of EMM treatments and explore new therapies to improve the prognosis of EMM. This article summarizes the recent advances in the treatment of EMM, including chemotherapy, HSCT, cellular immunotherapy and molecular targeted therapy. \u0000 \u0000 \u0000Key words: \u0000Multiple myeloma; Antineoplastic combined chemotherapy protocols; Hematopoietic stem cell transplantation; Molecular targeted therapy; Extramedullary myeloma; Chimeric antigen receptor-based immunotherapy","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"435-440"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44556260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.04.013
Yanhua Wang, Li-hong Hou
Hepcidin is a cysteine-rich antibacterial peptide synthesized and secreted by the liver, which plays a negative regulatory role in the regulation of iron balance in the body. At the same time, it can express a large amount in the immune process and participate in the body′s immune response. Hepcidin expression is affected by many factors, such as inflammation, hypoxia and signal transduction factors. Hepcidin gene expression is mainly regulated by signaling pathways, such as JAK/STAT, BMP/Smad, TLRs/MyD88, PI3K/AKT etc.. This article mainly discusses the iron metabolism, the relationship between hepcidin and iron metabolism, and its regulatory mechanisms. Key words: Iron metabolism disorders; Bone morphogenetic protein 6; Signal transduction; Interleukin-6; Hepcidin
{"title":"Research progress in expression and regulation mechanism of hepcidin","authors":"Yanhua Wang, Li-hong Hou","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.04.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.04.013","url":null,"abstract":"Hepcidin is a cysteine-rich antibacterial peptide synthesized and secreted by the liver, which plays a negative regulatory role in the regulation of iron balance in the body. At the same time, it can express a large amount in the immune process and participate in the body′s immune response. Hepcidin expression is affected by many factors, such as inflammation, hypoxia and signal transduction factors. Hepcidin gene expression is mainly regulated by signaling pathways, such as JAK/STAT, BMP/Smad, TLRs/MyD88, PI3K/AKT etc.. This article mainly discusses the iron metabolism, the relationship between hepcidin and iron metabolism, and its regulatory mechanisms. \u0000 \u0000 \u0000Key words: \u0000Iron metabolism disorders; Bone morphogenetic protein 6; Signal transduction; Interleukin-6; Hepcidin","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"358-361"},"PeriodicalIF":0.0,"publicationDate":"2019-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45923540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.04.004
Guo-hui Li, Yu-zhen Fan, Ren′an Chen, W. Qin, Yueru Ji, Cong Liu, N. Zhou, Yi Chen, Huaipeng Guo, Li Liu
Objective To analyze the long-term survival and prognostic factors of patients with acute promyelocytic leukemia (APL) who were treated with arsenic trioxide (ATO). Methods From January 2007 to December 2017, a total of 154 newly diagnosed APL patients who were treated with ATO were included in the study from Tangdu Hospital, Air Force Military Medical University. According to the time of diagnosis and the treatment regimen, the subjects were divided into all trans-retinoic acid (ATRA) + chemotherapy-induced group (n= 87, diagnosed before 2012) and ATRA + ATO double-induced group (n= 67, diagnosed after 2012). The retrospective investigation method was used to collect early mortality, complete remission (CR) rate, conversion rate of PML/RARΑ fusion gene, recurrence rate, peripheral blood granulocyte ratio, bone marrow granulocyte ratio, PML/RARα fusion gene phenotype, risk stratification, CD2 and CD34 expression in ATRA+ chemotherapy-induced group and ATRA+ ATO double-induced group. And the efficacy and prognosis were compared between two groups. The follow-up time of this study was up to June 30, 2018, with a median follow-up of 58 months (6-134 months). The Chi-square test or Fisher′s exact test were used to compare the early mortalities, CR rates, and PML/PARα fusion gene conversion rates between the ATRA + chemotherapy-induced group and the ATRA + ATO double-induced group. The Kaplan-Meier method was used to map the survival curves of the patients in both groups. The life table method was used to compare the overall survival (OS) rate and recurrence-free survival (RFS) rates of patients in both groups. Univariate analysis was used to determine the influencing factors affecting the prognosis of patients with APL. The procedure followed in this study was in line with the requirements of Helsinki Declaration of the Word Medical Association revised in 2013. All individuals were routinely signed with informed consent for chemotherapy and toxic drugs before treatment. Results ① The CR rate of all patients in this study was 92.8% (143/154). The CR rate in ATRA + chemotherapy-induced group was 89.6% (60/67), and that of the ATRA + ATO double-induced group was 95.4 % (83/87), the difference was not statistically significant (χ2 = 1.953, P=0.162). There was significant difference in conversion rate of PML/RARα fusion gene between ATRA + chemotherapy-induced group and ATRA + ATO double-induced group(98.9% vs 89.5%; χ2=4.891, P=0.027). The early mortality during induction therapy was 7.1% (11/154). ② In the 154 APL patients, eleven patients had recurrence during consolidation and maintenance treatment. The recurrence rates of ATRA + chemotherapy-induced group and ATRA + ATO double induction group were 13.4% (9/67) and 2.3%(2/87), respectively, and the difference was statistically significant(χ2=5.495, P=0.019). ③ The 5-year OS rate and RFS rate in ATRA+ chemotherapy-induced group were 83.6% and 85.0%, respectively, which of ATO + ATRA double
{"title":"Efficacy and prognosis of arsenic trioxide in treatment of patients with acute promyelocytic leukemia","authors":"Guo-hui Li, Yu-zhen Fan, Ren′an Chen, W. Qin, Yueru Ji, Cong Liu, N. Zhou, Yi Chen, Huaipeng Guo, Li Liu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.04.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.04.004","url":null,"abstract":"Objective \u0000To analyze the long-term survival and prognostic factors of patients with acute promyelocytic leukemia (APL) who were treated with arsenic trioxide (ATO). \u0000 \u0000 \u0000Methods \u0000From January 2007 to December 2017, a total of 154 newly diagnosed APL patients who were treated with ATO were included in the study from Tangdu Hospital, Air Force Military Medical University. According to the time of diagnosis and the treatment regimen, the subjects were divided into all trans-retinoic acid (ATRA) + chemotherapy-induced group (n= 87, diagnosed before 2012) and ATRA + ATO double-induced group (n= 67, diagnosed after 2012). The retrospective investigation method was used to collect early mortality, complete remission (CR) rate, conversion rate of PML/RARΑ fusion gene, recurrence rate, peripheral blood granulocyte ratio, bone marrow granulocyte ratio, PML/RARα fusion gene phenotype, risk stratification, CD2 and CD34 expression in ATRA+ chemotherapy-induced group and ATRA+ ATO double-induced group. And the efficacy and prognosis were compared between two groups. The follow-up time of this study was up to June 30, 2018, with a median follow-up of 58 months (6-134 months). The Chi-square test or Fisher′s exact test were used to compare the early mortalities, CR rates, and PML/PARα fusion gene conversion rates between the ATRA + chemotherapy-induced group and the ATRA + ATO double-induced group. The Kaplan-Meier method was used to map the survival curves of the patients in both groups. The life table method was used to compare the overall survival (OS) rate and recurrence-free survival (RFS) rates of patients in both groups. Univariate analysis was used to determine the influencing factors affecting the prognosis of patients with APL. The procedure followed in this study was in line with the requirements of Helsinki Declaration of the Word Medical Association revised in 2013. All individuals were routinely signed with informed consent for chemotherapy and toxic drugs before treatment. \u0000 \u0000 \u0000Results \u0000① The CR rate of all patients in this study was 92.8% (143/154). The CR rate in ATRA + chemotherapy-induced group was 89.6% (60/67), and that of the ATRA + ATO double-induced group was 95.4 % (83/87), the difference was not statistically significant (χ2 = 1.953, P=0.162). There was significant difference in conversion rate of PML/RARα fusion gene between ATRA + chemotherapy-induced group and ATRA + ATO double-induced group(98.9% vs 89.5%; χ2=4.891, P=0.027). The early mortality during induction therapy was 7.1% (11/154). ② In the 154 APL patients, eleven patients had recurrence during consolidation and maintenance treatment. The recurrence rates of ATRA + chemotherapy-induced group and ATRA + ATO double induction group were 13.4% (9/67) and 2.3%(2/87), respectively, and the difference was statistically significant(χ2=5.495, P=0.019). ③ The 5-year OS rate and RFS rate in ATRA+ chemotherapy-induced group were 83.6% and 85.0%, respectively, which of ATO + ATRA double","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"296-304"},"PeriodicalIF":0.0,"publicationDate":"2019-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46374105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.04.007
Jinkun Yang, Y. Li
Objective To systematically evaluate the clinical effects of abdominal aortic balloon occlusion in resection of pelvic and sacral tumors. Methods All the randomized controlled trials (RCT) and cohort studies about abdominal aortic balloon occlusion in resection of pelvic and sacral tumors were electronically collected by searching databases, including China National Knowledge Infrastructure (CNKI), Wanfang Database, China Biology Medicine disc (CBMdisc), PubMed, Embase, Cochrane Library Database. Search time interval period was from construction of databases to December 31, 2018. Cochrane bias risk assessment table was used to evaluate the quality of RCT, and New Castle-Ottawa Scale (NOS) was used to evaluate the quality of cohort studies. Two researchers independently screened the literatures according to the inclusion and exclusion criteria, evaluated the quality of the included literatures and risk of bias, and extracted relevant research data. Meta-analysis of the clinical effects of abdominal aortic balloon occlusion for pelvic and sacral tumor resection was performed by RevMan5.3 software. Outcome observation indicators included intraoperative blood loss, intraoperative blood transfusion volume, operation duration time and incidences of postoperative complications. Results ① A total of 219 related literatures were screened out in this study. Six of them met the inclusion and exclusion criteria of literatures, which included 1 RCT and 5 retrospective cohort studies. A total of 609 patients with pelvic and sacral tumor resection were involved in these 6 literatures. Among them, 258 patients underwent abdominal aortic balloon occlusion, and 351 did not receive abdominal aortic balloon occlusion. ② Cochrane bias risk assessment results of 1 RCT were uncertain, and NOS scores of 5 retrospective cohort studies were 7 scores. According to the results of literature quality evaluation, 5 high-quality cohort studies were included in the Meta-analysis. ③ Meta-analysis of this study showed that the intraoperative blood loss, intraoperative blood transfusion volume, operation duration time (excluded clinical heterogeneity) of patients undergoing abdominal aortic balloon occlusion for pelvic and sacral tumors resection were significantly lower than those of patients without abdominal aortic balloon occlusion (SMD=-917.12, 95%CI: -1 239.61 to -594.62, P 0.05). Conclusions Abdominal aortic balloon occlusion can reduce the amount of bleeding and blood transfusion during pelvic and sacral tumor resection without increasing the incidence of complications, including nerve injury, wound infection, urethral injury and vaginal injury. Key words: Balloon occlusion; Aortic, abdominal; Sacrum; Pelvic tumor; Blood loss, surgical; Blood transfusion; Postoperative complications
{"title":"Meta-analysis of clinical effects of abdominal aortic balloon occlusion in resection of pelvic and sacral tumors","authors":"Jinkun Yang, Y. Li","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.04.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.04.007","url":null,"abstract":"Objective \u0000To systematically evaluate the clinical effects of abdominal aortic balloon occlusion in resection of pelvic and sacral tumors. \u0000 \u0000 \u0000Methods \u0000All the randomized controlled trials (RCT) and cohort studies about abdominal aortic balloon occlusion in resection of pelvic and sacral tumors were electronically collected by searching databases, including China National Knowledge Infrastructure (CNKI), Wanfang Database, China Biology Medicine disc (CBMdisc), PubMed, Embase, Cochrane Library Database. Search time interval period was from construction of databases to December 31, 2018. Cochrane bias risk assessment table was used to evaluate the quality of RCT, and New Castle-Ottawa Scale (NOS) was used to evaluate the quality of cohort studies. Two researchers independently screened the literatures according to the inclusion and exclusion criteria, evaluated the quality of the included literatures and risk of bias, and extracted relevant research data. Meta-analysis of the clinical effects of abdominal aortic balloon occlusion for pelvic and sacral tumor resection was performed by RevMan5.3 software. Outcome observation indicators included intraoperative blood loss, intraoperative blood transfusion volume, operation duration time and incidences of postoperative complications. \u0000 \u0000 \u0000Results \u0000① A total of 219 related literatures were screened out in this study. Six of them met the inclusion and exclusion criteria of literatures, which included 1 RCT and 5 retrospective cohort studies. A total of 609 patients with pelvic and sacral tumor resection were involved in these 6 literatures. Among them, 258 patients underwent abdominal aortic balloon occlusion, and 351 did not receive abdominal aortic balloon occlusion. ② Cochrane bias risk assessment results of 1 RCT were uncertain, and NOS scores of 5 retrospective cohort studies were 7 scores. According to the results of literature quality evaluation, 5 high-quality cohort studies were included in the Meta-analysis. ③ Meta-analysis of this study showed that the intraoperative blood loss, intraoperative blood transfusion volume, operation duration time (excluded clinical heterogeneity) of patients undergoing abdominal aortic balloon occlusion for pelvic and sacral tumors resection were significantly lower than those of patients without abdominal aortic balloon occlusion (SMD=-917.12, 95%CI: -1 239.61 to -594.62, P 0.05). \u0000 \u0000 \u0000Conclusions \u0000Abdominal aortic balloon occlusion can reduce the amount of bleeding and blood transfusion during pelvic and sacral tumor resection without increasing the incidence of complications, including nerve injury, wound infection, urethral injury and vaginal injury. \u0000 \u0000 \u0000Key words: \u0000Balloon occlusion; Aortic, abdominal; Sacrum; Pelvic tumor; Blood loss, surgical; Blood transfusion; Postoperative complications","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"319-326"},"PeriodicalIF":0.0,"publicationDate":"2019-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46995330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.04.008
Ying Zhao, Jianying Yang
Objective To explore the population characteristics of voluntary blood donors in Chengdu from 2012 to 2018, and provide reference basis for establishing scientific and reasonable donor recruitment measures to ensure adequate blood supply. Methods From 2012 to 2018, a total of 1 310 305 voluntary blood donors in Chengdu Blood Center were selected as subjects. Among them, there were 680 439 male and 629 866 female donors. The population characteristics information of all blood donors were collected from the Qiao Information Management System of Blood Station V9.0, and the Informed Consent and Health Questionnaire for Blood Donors. The population characteristics of the voluntary blood donors included gender, age, educational level and occupation. The growth rates of the blood donors in each year and the composition ratios of the blood donors with different population characteristics were calculated. The composition ratios of the blood donors with different population characteristics in each year were compared by Chi-square test, and the trend of the composition ratios of the blood donors from 2012 to 2018 was analyzed by trend Chi-square test. The procedure followed in this study was in line with the requirements of the Helsinki Declaration of the World Medical Association revised in 2013. All blood donors signed the Informed Consent of Blood Donors. Results ① From 2012 to 2018, there were 1 310 305 voluntary blood donors in Chengdu. The number of the voluntary blood donors from 2012 to 2018 were 156 095, 164 003, 174 990, 186 215, 197 825, 211 131 and 220 046 cases respectively, which showed an increasing trend year by year, with an annual average growth rate of 6.83%. The year-to-year growth rates of the voluntary blood donors in Chengdu from 2012 to 2018 were 5.07%, 6.70%, 6.41%, 6.23%, 6.73% and 4.22%, respectively. The year-to-year growth rate increased rapidly from 2014 to 2017 and slowed down from 2017 to 2018. ② Among the 1 310 305 voluntary blood donors in Chengdu from 2012 to 2018, the differences of composition ratios among blood donors with the different genders, ages, occupations and educational levels were statistically significant (χ2= 68.625, 26 695.385, 132.679, 30 324.809; P<0.001), respectively. Among the blood donors of different ages, the composition ratios of blood donors in the 18 to 25 age group showed a downward trend, but that of 46 to 60 age group were upward trend (χtrend2=18 577.754, P<0.001). Among blood donors of different occupations, the composition ratios in farmers donors showed an upward trend (χtrend2= 3 885.708, P<0.001). Conclusions From 2012 to 2018, the number of the voluntary blood donors in Chengdu increased gradually. The distributions of the voluntary blood donors in different genders, ages, educational levels and occupations have their own characteristics. Different recruitment strategies should be performed according to the different groups. Key words: Population characteristics
{"title":"Investigation on population characteristics of voluntary blood donors in Chengdu from 2012 to 2018","authors":"Ying Zhao, Jianying Yang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.04.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.04.008","url":null,"abstract":"Objective \u0000To explore the population characteristics of voluntary blood donors in Chengdu from 2012 to 2018, and provide reference basis for establishing scientific and reasonable donor recruitment measures to ensure adequate blood supply. \u0000 \u0000 \u0000Methods \u0000From 2012 to 2018, a total of 1 310 305 voluntary blood donors in Chengdu Blood Center were selected as subjects. Among them, there were 680 439 male and 629 866 female donors. The population characteristics information of all blood donors were collected from the Qiao Information Management System of Blood Station V9.0, and the Informed Consent and Health Questionnaire for Blood Donors. The population characteristics of the voluntary blood donors included gender, age, educational level and occupation. The growth rates of the blood donors in each year and the composition ratios of the blood donors with different population characteristics were calculated. The composition ratios of the blood donors with different population characteristics in each year were compared by Chi-square test, and the trend of the composition ratios of the blood donors from 2012 to 2018 was analyzed by trend Chi-square test. The procedure followed in this study was in line with the requirements of the Helsinki Declaration of the World Medical Association revised in 2013. All blood donors signed the Informed Consent of Blood Donors. \u0000 \u0000 \u0000Results \u0000① From 2012 to 2018, there were 1 310 305 voluntary blood donors in Chengdu. The number of the voluntary blood donors from 2012 to 2018 were 156 095, 164 003, 174 990, 186 215, 197 825, 211 131 and 220 046 cases respectively, which showed an increasing trend year by year, with an annual average growth rate of 6.83%. The year-to-year growth rates of the voluntary blood donors in Chengdu from 2012 to 2018 were 5.07%, 6.70%, 6.41%, 6.23%, 6.73% and 4.22%, respectively. The year-to-year growth rate increased rapidly from 2014 to 2017 and slowed down from 2017 to 2018. ② Among the 1 310 305 voluntary blood donors in Chengdu from 2012 to 2018, the differences of composition ratios among blood donors with the different genders, ages, occupations and educational levels were statistically significant (χ2= 68.625, 26 695.385, 132.679, 30 324.809; P<0.001), respectively. Among the blood donors of different ages, the composition ratios of blood donors in the 18 to 25 age group showed a downward trend, but that of 46 to 60 age group were upward trend (χtrend2=18 577.754, P<0.001). Among blood donors of different occupations, the composition ratios in farmers donors showed an upward trend (χtrend2= 3 885.708, P<0.001). \u0000 \u0000 \u0000Conclusions \u0000From 2012 to 2018, the number of the voluntary blood donors in Chengdu increased gradually. The distributions of the voluntary blood donors in different genders, ages, educational levels and occupations have their own characteristics. Different recruitment strategies should be performed according to the different groups. \u0000 \u0000 \u0000Key words: \u0000Population characteristics","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"327-331"},"PeriodicalIF":0.0,"publicationDate":"2019-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43801285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.04.002
Jia-yuan Chen, Yingjun Chang, H. Wei
Mixed phenotype acute leukemia (MPAL) is an uncommon subtype of acute leukemia (AL). It is characterized by the expression of multi-lineage immunophenotypic markers representing myeloid, T or B lymphoid lineage in leukemia cells. The diagnosis of MPAL refers to the World Health Organization (WHO) classification of myeloid neoplasms and AL proposed in 2016. Given the low prevalence and inferior prognosis of MPAL, it′s difficult to choose the optimal treatment for MPAL patients. Pathogenesis of MPAL remains largely unknown. Due to the development of biologic technology, researchers now have a better comprehension of this rare disease. This article reviews the advances of diagnosis, pathogenesis and treatment in MPAL. Key words: Leukemia, biphenotypic, acute; Diagnosis; Therapy; Pathogenesis mechanisms
{"title":"Current research status of diagnosis and therapy in mixed phenotype acute leukemia","authors":"Jia-yuan Chen, Yingjun Chang, H. Wei","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.04.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.04.002","url":null,"abstract":"Mixed phenotype acute leukemia (MPAL) is an uncommon subtype of acute leukemia (AL). It is characterized by the expression of multi-lineage immunophenotypic markers representing myeloid, T or B lymphoid lineage in leukemia cells. The diagnosis of MPAL refers to the World Health Organization (WHO) classification of myeloid neoplasms and AL proposed in 2016. Given the low prevalence and inferior prognosis of MPAL, it′s difficult to choose the optimal treatment for MPAL patients. Pathogenesis of MPAL remains largely unknown. Due to the development of biologic technology, researchers now have a better comprehension of this rare disease. This article reviews the advances of diagnosis, pathogenesis and treatment in MPAL. \u0000 \u0000 \u0000Key words: \u0000Leukemia, biphenotypic, acute; Diagnosis; Therapy; Pathogenesis mechanisms","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"283-288"},"PeriodicalIF":0.0,"publicationDate":"2019-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42258597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.04.003
Cuiyun Qu
Hematopoietic transcription factors (TF) are proteins that bind to specific DNA sequences and regulate expression of genes. Hematopoietic TF act in a combinatorial manner to bind sequence-specific DNA within promoter regions to regulate specific gene expression, either as activators or repressors. Hematopoietic TF gene mutations induce rippling downstream effects by simultaneously altering the expression of multiple genes. Mutations involving these hematopoietic TF affect diverse aspects of megakaryocyte biological function, and platelet production and function, culminating in thrombocytopenia and platelet dysfunction. Some hematopoietic TF mutations are associated with predisposition to hematologic malignancies. The molecular and genetic mechanisms in inherited platelet defects (IPD) are unknown. A growing number of evidences suggest that hematopoietic TF gene mutations are important underlying causes for defects in platelet production, morphology and function. The review summarizes the current scientific progress of hematopoietic TF gene mutations in IPD. Key words: Transcription factors; Hematopoietic system; Mutation; Blood platelet disorders; Thrombocytopenia; Inherited platelet defects
{"title":"Hematopoietic transcription factor gene mutations and inherited platelet defects","authors":"Cuiyun Qu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.04.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.04.003","url":null,"abstract":"Hematopoietic transcription factors (TF) are proteins that bind to specific DNA sequences and regulate expression of genes. Hematopoietic TF act in a combinatorial manner to bind sequence-specific DNA within promoter regions to regulate specific gene expression, either as activators or repressors. Hematopoietic TF gene mutations induce rippling downstream effects by simultaneously altering the expression of multiple genes. Mutations involving these hematopoietic TF affect diverse aspects of megakaryocyte biological function, and platelet production and function, culminating in thrombocytopenia and platelet dysfunction. Some hematopoietic TF mutations are associated with predisposition to hematologic malignancies. The molecular and genetic mechanisms in inherited platelet defects (IPD) are unknown. A growing number of evidences suggest that hematopoietic TF gene mutations are important underlying causes for defects in platelet production, morphology and function. The review summarizes the current scientific progress of hematopoietic TF gene mutations in IPD. \u0000 \u0000 \u0000Key words: \u0000Transcription factors; Hematopoietic system; Mutation; Blood platelet disorders; Thrombocytopenia; Inherited platelet defects","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"289-295"},"PeriodicalIF":0.0,"publicationDate":"2019-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45294501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：